Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission

NCT00055536 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00055536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2002
Completion date
July 31, 2003
Enrollment
60
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease